SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001725160-23-000148
Filing Date
2023-06-16
Accepted
2023-06-16 17:19:25
Documents
13
Period of Report
2023-06-16
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K zntl-20230616.htm   iXBRL 8-K 60944
2 EX-3.1 certificateofamendmenttoce.htm EX-3.1 6965
  Complete submission text file 0001725160-23-000148.txt   216378

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT zntl-20230616.xsd EX-101.SCH 1904
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT zntl-20230616_lab.xml EX-101.LAB 25852
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT zntl-20230616_pre.xml EX-101.PRE 13583
7 EXTRACTED XBRL INSTANCE DOCUMENT zntl-20230616_htm.xml XML 11711
Mailing Address 1359 BROADWAY, SUITE 801 NEW YORK NY 10018
Business Address 1359 BROADWAY, SUITE 801 NEW YORK NY 10018 (212) 433-3791
Zentalis Pharmaceuticals, Inc. (Filer) CIK: 0001725160 (see all company filings)

IRS No.: 823607803 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39263 | Film No.: 231022306
SIC: 2834 Pharmaceutical Preparations